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Health Technology Assessment in Poland) for orphan oncology drugs are based.
The role of AHTAPol is to prepare for the Minister of Health recommendations on
financing all medical technologies from public funds. Orphan oncology drugs un-
dergo pharmacoeconomic evaluations and coverage decision processes similar to
other molecules. AHTAPol’s reimbursement recommendations are based on evi-
dence of clinical benefit and efficacy/safety ratio, cost-effectiveness, costs and their
impact on the payer’s budget. METHODS: Among recommendations of AHTAPol
published until the end of May 2011, we identified all related to orphan oncology
drugs. Having categorized into types of recommendations then we analyzed ratio-
nal for granted decision. RESULTS: Among 420 AHTAPol decisions analyzed, 32
(21,7%) applied to non-drugs technologies, 91 (21,7%) to health care programs and
297 (70,7%) to drugs technologies. Among 297 drugs recommendations only 15 (5%)
was related to oncology orphan molecules. Granted were 10 (out of 15) positive
recommendations. For 3 out of 15 drugs AHTAPol issued conditional recommen-
dations (with restriction related to reducing the cost- effectiveness outcomes).
Only two orphan oncology drugs were assessed negatively. In both cases main
criteria on which recommendations were based refer to low clinical efficacy and
safety. CONCLUSIONS: Neither cost-effectiveness nor costs and budget impact
were significant arguments in negative recommendations of AHTAPol. As a matter
of fact, lack of clinical efficacy and insufficient safety profile were the key issues for
orphan oncology drugs negatively assessed by AHTAPol.
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REGIONAL DIFFERENCES AMONG METHADONE MAINTENANCE PROGRAMS IN
SPAIN
Vieta A, Hurtado P
IMS Health, Barcelona, Barcelona, Spain
OBJECTIVES: Methadone maintenance programs (MMP) offer the best treatment
for opioid dependence. In Spain, methadone hydrochloride is prepared as a magis-
tral formulation. Despite the organization and the management of the MMP is in
hands of the Delegación del Gobierno para el Plan Nacional sobre Drogas, each
autonomous region (AR) is responsible for its planning and financing. The aim of
this study was to identify planning MMP differences among AR in Spain.
METHODS: A structured literature review on the IME, SciELO, Doyma, Medline,
national and AR official bulletins and health web pages, and general and spe-
cialised press, up to July 1, 2010. RESULTS: Planning differences were found around
four areas. First, in 13 AR the regional health department establishes the health
care provision and legal framework for MMP, whereas in 4 AR this is a shared
responsibility between health and social security regional departments. Second,
three health care networks for the provision of MMP coexist in Spain. Andalusia
has drug care centers, 6 AR specialized or mental health centers and 10 AR combine
both structures. Third, in 11 AR methadone prescribing and dispensing is per-
formed in one center, in 6 AR in separate centers and in Cantabria coincide both
systems. Fourth, in the majority of AR a central laboratory or the hospitals elabo-
rate the greater part of the methadone; however, in 2 AR it is elaborated in phar-
macies and in 2 AR in the prescribing center. CONCLUSIONS: In Spain, patients are
not always normalized into the health care system. Methadone provided in the
MMP shows different elaboration, prescribing and dispensing processes across the
different AR. This may lead to heterogeneity in the magistral formulation of meth-
adone and patient access to it across the territory.
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ANALYSIS OF RESULTS OF THE REFERENCE PRICING OF TURKEY
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OBJECTIVES: IEGM (General Directorate of Pharmaceuticals and Pharmacy) is re-
sponsible for setting all human medicinal products prices. Reference pricing sys-
tem is used for setting prices. Reference countries are reviewed annually and may
be subject to certain alterations. The aim of this study is to show the distribution of
reference countries which were used for reference pricing. METHODS: The price
list of pharmaceuticals which was published by IEGM on 15.04.2011 was used for
the analysis. Distribution of reference countries and prices were evaluated.
RESULTS: Prices of 6251 jeneric and 3703 original products were set. 5283 of jenerics
and 3306 of originals were in the positive list for reimbursement. Reference pricing
was used for 2352 jenerics and 2281 originals. Prices of the remaing were set outside
of reference pricing. 32 different countries were used for reference pricing. Italy
was the most popular country for reference pricing (24.47%). Italy was followed by
Spain (21.96%), Greece (19.69%), France (11.8%) and Portugal (8.7%). Even if Germany
was not a reference country, Germany was used in 3.71% of pharmaceuticals. Other
25 countries were used by 13,29%. However the ranking was changed only in phar-
maceuticals with prices above 200 Turkish Liras (TL) or original pharmaceuticals;
Greece was the most popular country in these rankings by 27.85% and 24.25%,
respectively. Italy was the most popular country for reference pricing in sub groups
like generics, prices ranging between 0 and 50 TL, 50 and 100 TL, and 100 and 200 TL.
CONCLUSIONS: It has been shown that Italy has the highest impact on the pricing
of all pharmaceuticals in Turkey. Greece has the highest impact on the pricing of
originals. Even if Germany was not a reference country, it has been seen that it
affects pharmaceuticals more than other countries which were also not used for
reference pricing.
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PAYER PERSPECTIVES ON EVIDENCE FOR FORMULARY DECISION MAKING IN
THE UNITED STATES
Wang A, Baerwaldt T, Kuan R, Nordyke R, Halbert R
PriceSpective LLC, El Segundo, CA, USA
OBJECTIVES: The role that payers play in the pharmaceutical market has been
increasing in prominence. Much research has focused on public payers and how
drug reimbursement policies change in response to data from drug effectiveness
studies. However, the commercial payer perspective has not been well researched.
This study seeks to describe how U.S. commercial payers use different types of
comparative evidence to make reimbursement and formulary placement
decisions. METHODS: We recruited 20 US commercial payers who currently par-
ticipate in or lead pharmaceutical and therapeutics committees for their plans. Our
participants represent managed care organizations that cover a total of more than
95 million members. We conducted semi-structured qualitative interviews com-
prised of five representative scenarios and asked payers to rate how they value
different study designs for each scenario. The interviews were transcribed, the
responses were tabulated, and then analyzed for content. RESULTS: The reported
value of the study designs differed between national and regional payers as well as
between medical and pharmacy directors. National payers have more resources
and are more likely to value and conduct retrospective analyses and decision mod-
eling than regional payers. Pharmacy directors tend to favor retrospective analyses
and medical directors value RCTs, pragmatic trials, and prospective non-experi-
mental studies. Although RCTs were often the highest ranked study design, payers
still found prospective non-experimental studies and retrospective analyses valu-
able for certain uses. Payers are currently unable to manage most oncology prod-
ucts beyond labeled indications due to political pressure to cover all drugs regard-
less of price. CONCLUSIONS: Payers value and utilize data from a broad range of
study designs to inform formulary placement decisions. However, the disease
state, market condition, and type of payer will influence what sort of comparative
evidence is of the most value.
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OBJECTIVES: Emergency Department (ED) overcrowding (OC) is plaguing EDs
worldwide with grave implications on patient and caregiver comfort and quality of
care. Alleviating this problem tops agendas of governmental and professional
agencies. Many contributing factors have been cited and many approaches have
been tried, without widespread success. Focused Operations Management (FM)
integrates novel managerial theories and practical tools {such as the theory of
constraints (TOC) and the Pareto diagram} into a systematic approach, helping
managers to analyze complex operational systems, find bottlenecks and root
causes and finally, chart routes to improved throughput and quality. This approach
has proved effective in the industry and service sectors, radically improving per-
formance at little additional cost. The FM approach has never been implemented in
the ED and could considerably enhance the management of its operations. In this
first phase of the research, we use semi-structured interviews with experts, to
identify potential high-yield interventions. METHODS: A review of the ED opera-
tions literature was performed to identify major ED operational challenges, metrics
and alleviating measures. Semi-structured interviews with ED head nurses and
managers, hospital administrators and Health ministry administrators were con-
ducted. The interviews centered on validation of major challenges identified in the
literature search and assessing potential utility of FM tools. RESULTS: The major
challenges we identified included ED boarding, prolonged length of stay, unjusti-
fied ED utilization and slow access to specialist consults, lab tests and imaging
studies. Of the FM tools presented to specialists, those assessed to be most prom-
ising were ”the “complete kit” concept and TOC methods to identify and alleviate
bottle necks and to reduce “work in progress”. CONCLUSIONS: implementation of
the novel FM management strategies has enhanced operations and performance in
many industries and services. The ED is in dire need and a good candidate for the
use of these tools.
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USE OF PAEDIATRIC “OBSERVATION STATUS” AND EFFECT ON IN-PATIENT
ADMISSION RATE IN ACCIDENT AND EMERGENCY (A&E) DEPARTMENTS
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OBJECTIVES: To describe the use of paediatric “observation status” in the accident
and emergency department (A&E). METHODS: A prospective survey was per-
formed in 12 Belgian hospitals during 2 weeks straddling October and November
2010. All patients (16 years) attending A&E were included. “Observation status”
was defined when after the first medical evaluation, instead of hospitalization or
home discharge, the situation required further observation of the patient. The
clinicians in charge were asked at the start of the “observation” period to prognos-
ticate whether the child would be discharged or admitted. RESULTS: Among 3220
children included in the study, the observation rate was 38.6%. The characteristics
of these children were as follows. Median age: 5.0 years old (IQR: 1.7-11.3), boys:
53.5%. The median length of stay in A&E was 110 minutes (IQR: 65-175) and 14.3%
were admitted as in-patient. The most common observations concerned orthopae-
dic, medical digestive and respiratory affections. The three main reasons for ob-
servation were additional procedures (69.0%), diagnostic determination (10.7%),
and treatment testing (8.3%). Most of the observations (86.9%) were performed in a
waiting room (not in a bed), 9.7% in an observation unit dedicated to children and
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3.4% in an observation unit to adults. Only 4.1% of the observations satisfied the
French paediatric short-stay definition (patient in a bed monitored hourly). Com-
pared to the clinicians’ prognosticated rate, 1.3% less children were admitted as
in-patients. CONCLUSIONS: Despite the absence of financial and regulatory frame
in Belgium, observation is a frequent modality of care. Observation helped to refine
diagnosis and treatments and to reduce in-patient admission rate. However, with
regards to the French guidelines less than 5% could be qualified as paediatric A&E
short-stay. Flexible observation units should be recommended.KEYWORDS: Emer-
gency, paediatrics, short-stay, observation status
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OBJECTIVES: Explore the variability of two sets of tariffs/public prices across Au-
tonomous Communities (ACs) in Spain. METHODS: Tariffs/public prices for DRGs
and ICD-9 procedure items from all 17 Spanish AC were extracted from official
listings. For ICD-9, items appearing in at least 5 ACs were selected. Per item, vari-
ability in tariffs/public prices across ACs was measured using the coefficient of
variation (CV) where greater CV indicates larger variability. Variability in DRG lev-
els across ACs was assessed for a sub-set of 16 items. We developed a simple
relative index whereby a tariff in a region was divided by the average tariff across
all regions and then an overall index was computed as the simple mean of all items
for each AC. RESULTS:Nine out of 17 ACs list DRGs. Navarra had the most complete
list (681 items) and Catalonia the least complete (50 items). The lowest CV was for
“spinal procedures” (DRG #4, mean: 10,335€, CV: 0.016, N2) and the greatest for
“abdominal interventions to neonates” (DRG 624, mean: 8139€, CV: 1248, N6). On
average, across the sub-set of 16 DRGs, Catalonian tariffs were 63% below and La
Rioja tariffs were 31% above the average across 9 ACs. ICD-9 tariffs were identified
in 6 out of 17 ACs, and variability for 48 codes that were listed in at least 4 ACs was
lowest for “repair of uterine support structures” (ICD-9 #69.2, mean: 1210€, CV: 0.07,
N4) and greatest for “local excision of breast lesion” (ICD-9 #85.21, mean: 710€, CV:
0.83, N4).CONCLUSIONS:Results show great variability amongst AC tariff listings
in Spain. Some ACs tend towards consistently higher or lower tariff levels, com-
pared to the average across ACs. Differences are difficult to explain and suggest
that tariffs and pubic prices do not reflect actual costs, but may be arbitrary esti-
mates.
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REIMBURSING TELEMONITORING IN EUROPE: ARE PAYERS READY?
Flostrand S1, Garde E2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Sanofi, Paris, France, 3University Claude Bernard Lyon 1, Lyon,
France
OBJECTIVES: As evidence and experience of telemonitoring grows, health care
payers are confronted with multiple challenges to reimburse these new healthcare
solutions. This study evaluated the current reimbursement systems in five Euro-
pean markets (France, Germany, Italy, Spain, and the UK) to determine readiness
for telemonitoring and to identify changes required to permit telemonitoring to
develop in the future. METHODS: To identify current telemonitoring funding, we
reviewed the sources and mechanisms used to pay for pilot projects, and then
reviewed national and regional health care funding systems to evaluate the read-
iness to finance telemonitoring. RESULTS: There are important differences in fi-
nancing telemonitoring among European countries. While pilots exist in all coun-
tries, these are financed on a project basis from European Union, national or
regional funds, outside regular healthcare budgets. Budget silos, disease reference
group (DRG) changes and contractual funding are key barriers to payer readiness
for telemonitoring. In Germany, only one telemonitoring DRG act is defined, while
in France and Italy, defining telemonitoring acts for reimbursement is underway.
In these countries, payers are reluctant to pay for the monitoring and alert service
component. In Spain, regional authorities are advancing pilots at different speeds
but system reforms have not yet been undertaken. Only in the UK, the English NHS
has moved from pilots to deployment through financing at the Primary Care Trust
level. CONCLUSIONS: European reimbursement systems do not yet accommodate
telemonitoring, and pilots and device purchases will not sustain this therapeutic
solution. To enable telemonitoring, payers need to establish new codes and rules to
pay for telemonitoring acts by health care professionals, and decide how to pay for
the most complex element: the monitoring and alert service component. Options
include: no reimbursement (the current option), a periodic fixed fee or capitation.
Any option requires careful framing and the benefits of telemonitoring need fur-
ther evaluation.
PHP100
DID IQWIG‘S DRUG APPRAISALS IN CONNECTION WITH G-BA‘S DIRECTIVES
CHANGE PRESCRIBING BEHAVIOR OF GERMAN PHYSICIANS?
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OBJECTIVES: To assess the impact of different formats of G-BA‘s (Federal Joint
Committee) directives had on the prescription behavior of health care profession-
als (HCPs) prior to the introduction of the AMNOG legislation (i.e. Directives re-
structuring the German pharmaceutical market).METHODS:A retrospective study
of the IQWiG’s (Institute for Quality and Efficiency in Healthcare) review of phar-
maceutical products covered by a G-BA directive during a 5-year period (2005-2010).
An event list reporting the interaction of G-BA, IQWiG and BMG (German Minister
of Health) was compiled by systematic searches of official websites. Regression
analyses retrieved from IMS data bases (Intercontinental Marketing Services) were
conducted defining a 95% confidence interval. Time points where actual sales ex-
ceeded or deceeded this confidence interval were reconciled with the list of events
concluding if and what kind of events had impacted unit sales. RESULTS: G-BA
required a mean of 1304 days to generate a directive followed by 567 days required
by IQWiG to complete its review. IQWiG achieved a mean output of 15 projects per
year, which is half of what NICE achieved in the same period. The format of the
final directive had a strong influence on the overall review. These findings indicate
that G-BA’s directives did not influence the annual number of prescriptions during
the five year period. CONCLUSIONS: The new set of laws – commonly known as
AMNOG is targeting two important weaknesses of the previous systems, which are
clearly identified by this study. Thus, clear ambitious timelines should be defined,
especially for the most time consuming review stages, namely completion of the
report plan and adherence to the principle of evidence based medicine for all
reviews.
PHP101
BIOSIMILARS ARE NOT GENERICS FROM PAYER PERSPECTIVE
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OBJECTIVES: To review the barriers and opportunities in market access for
biosimilars. METHODS: Both primary & secondary research were used in this
study. Primary research was conducted with payers, physicians, pharmaceuticals
and biosimilar manufactures. RESULTS: The US and EU are currently the largest
consumers of biologics in the world; however, other markets are expected to see
strong growth in their use of biologics over the next few years. Although many
biologics are expected to go off-patent in the next few years, (thereby creating an
attractive opportunity for biosimilars); the complex structure of biologics makes
the manufacturing process of biosimilars extremely difficult, and with EU legisla-
tion currently requiring phase I-III clinical trials to be conducted for all new bio-
similars the developmental costs and barriers to entry of biosimilars are high. With
respect to the costs per treatment, the price of biologics are significantly higher
than for small molecules creating a use-limiting factor in many markets; for this
reason biosimilars are recognised by payers and physicians as being cost-effective
in the sense of being able to provide the same treatment but at a lower cost (20%
cheaper). However, payers confirmed that cost-saving alone will not ensure access
for biosimilars and physicians are hesitant to adopt biosimilars due to safety and
efficacy concerns. CONCLUSIONS: With the use of biologics rapidly increasing,
patent expiries expected to occur in the near future and the low numbers of com-
petitors, companies are presented with a new and attractive market with the pro-
duction of biosimilars. Although there are several challenges to entering the mar-
ket (including the intense approval process) biosimilars are recognized and are
treated differently from generics by payers. With drug costs increasing and con-
cerns over the safety and efficacy of biosimilars, reduced costs of biosimilars to-
gether with clinical reassurance will enable broader acceptance and usage of bio-
similars in most markets.
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BIOSIMILARS: PRICING & REIMBURSEMENT IN GERMANY: KEY INSIGHTS FROM
SICKNESS FUNDS
Chaudhari SD, Bache B
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OBJECTIVES: While the European biosimilars market is still in its infancy, these
products are facing tough market access conditions and have yet to match the
success of small-molecule generics. With the increasing cost consciousness of the
payers and potentially safety concerns, it is imperative to explore the key pricing
and reimbursement drivers and barriers for biosimilars from the payer-lens. In
addition, the research aims to provide insights into strategies for their successful
‘market access’ in the German healthcare system. METHODS: This research was
based on a combination of secondary and primary research to evaluate the key
success factors for biosimilars. Secondary research of published data such as G-
BA’s assessment of biosimilars, current policies, sector-specific research articles
contributed towards a framework to understand the key factors affecting payer’s
attitudes towards biosimilars, which was then validated through a telephone sur-
vey of 10 sickness funds in 2011. RESULTS: A multitude of factors determine price
sustainability for biosimilars in Germany. The attitudes of sickness funds toward
biosimilars vary, which affect price dynamics as well as the cost containment
measures to encourage/ inhibits its use. While the use and prescribing of biosimi-
lars are subject to quotas and guidelines encouraging its use, some sickness funds’
focus on price is moderated by concerns about the safety of biosimilars. Overall, in
order to provide access to these products, payers are increasingly raising data
requirements. CONCLUSIONS: There exits significant inter-payer variability in the
extent of inter-changeability and data expectation from future biosimilars. Payer
expectations vary, based on the stage of the disease/ indications, the level of unmet
need, and the number of available alternatives. In a climate of increasing pricing
concerns, securing marketing approval is no longer the end of the road for biosimi-
lars. Hence, unlike generics, biosimilars cannot be merely ‘sold’ but need to be
‘marketed’.
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GLOBAL HEALTH CARE REFORMS AND PRICING, ACCESS AND HEALTH
OUTCOMES STRATEGY
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